NEW YORK, April 7, 2023 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is reminding investors that a class action lawsuit has been filed against Caribou Biosciences, Inc. (“Caribou” or the “Company”) CRBU in the United States District Court for the Northern District of California on behalf of all individuals and entities that purchased or otherwise acquired Caribou securities pursuant to and/or attributable to the November 20, 2020 IPO; pursuant to and/or traceable to the SPO of March 18, 2021 and/or between November 20, 2020 and September 19, 2022, both dates inclusive (the “Collection Period”). Investors have until April 11, 2023 to petition the court to be named lead plaintiff in the lawsuit.

Click Here to take part in the action.

Caribou is a clinical-stage biopharmaceutical company developing genome-edited allogeneic cell therapies for the treatment of hematological malignancies and solid tumors in the US and internationally. The Company is developing, among other product candidates, CB-010, an allogeneic anti-CD19 CAR T-cell therapy1, which is in a Phase 1 clinical trial termed “ANTLER” for the treatment of relapsed or refractory B-cell non- Hodgkin found lymphoma (“r/r B-NHL”).

According to the defendants, CB-010 is the first clinical-stage allogeneic anti-CD19 CAR-T cell therapy in which programmed cell death protein 1 (“PD-1”) has been removed from the CAR-T cell surface by a genome-edited knockout of the PDCD1 gene that is said to distinguish CB-010 from other allogeneic CAR-T cells by, among other things, enhancing the “persistence” of anti-tumor activity.

On July 1, 2021, Caribou filed a registration statement on Form S-1 with the SEC in connection with the IPO, which, after several amendments, was declared effective by the SEC on July 22, 2021 (the “Registration Statement”).

On July 23, 2021, Caribou common stock began public trading on the Nasdaq Global Select Market (“NASDAQ”) pursuant to the registration statement…